Trials / Conditions / Fragile X Syndrome

Fragile X Syndrome

93 registered clinical trials studyying Fragile X Syndrome — 18 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM) NCT07209462	Mirum Pharmaceuticals, Inc.	Phase 2
Not Yet Recruiting	Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome NCT06261502	Université de Sherbrooke	Phase 2
Not Yet Recruiting	Effect of CBD on the Brain NCT06261450	Université de Sherbrooke	Phase 2
Recruiting	Physical Activity and Community EmPOWERment Project NCT06740162	University of North Carolina, Chapel Hill	N/A
Recruiting	Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414	Assistance Publique - Hôpitaux de Paris	—
Recruiting	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorde NCT06081348	Holland Bloorview Kids Rehabilitation Hospital	Phase 2
Completed	Study of SPG601 in Adult Men With Fragile X Syndrome NCT06413537	Spinogenix	Phase 2
Completed	Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS) NCT06334419	Craig Erickson	Phase 2
Recruiting	Probiotic Intervention for Microbiome Modifications and Clinical Improvements in Fragile X Syndrome NCT06279858	Specila hospital for cerebral palsy and developmental neurology	N/A
Recruiting	Speech-in-noise Perception in Autism and Fragile X NCT06088589	Children's Hospital Medical Center, Cincinnati	N/A
Recruiting	Web Intervention for Parents of Youth With Genetic Syndromes (WINGS) NCT06139172	Rush University Medical Center	N/A
Completed	CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction NCT06480968	Connecta Therapeutics, S.L.	Phase 1
Unknown	Optical Imaging as a Tool for Monitoring Brain Function in Fragile X Syndrome NCT06293027	IRCCS Fondazione Stella Maris	—
Recruiting	Alpha Auditory Entrainment for Cognitive Enhancement and Sensory Hypersensitivity in Youth With Developmental NCT06227780	Children's Hospital Medical Center, Cincinnati	N/A
Suspended	An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome NCT05832255	Nova Mentis Life Science Corp	Phase 2
Enrolling By Invitation	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities NCT05301361	University of California, Davis	Phase 1
Completed	A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome NCT05358886	Tetra Discovery Partners	Phase 3
Active Not Recruiting	An Open-Label Extension Study of BPN14770 in Subjects With Fragile X Syndrome NCT05367960	Tetra Discovery Partners	Phase 3
Recruiting	Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG- Infant NCT06560242	Children's Hospital Medical Center, Cincinnati	N/A
Recruiting	Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG-Preschool Age NCT05957549	Children's Hospital Medical Center, Cincinnati	N/A
Active Not Recruiting	Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge NCT05418049	Children's Hospital Medical Center, Cincinnati	Phase 2
Withdrawn	Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40 NCT04823052	Healx Limited	Phase 2
Completed	A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X Syndrome NCT05163808	Tetra Discovery Partners	Phase 2 / Phase 3
Recruiting	Metformin in Children With Fragile X Syndrome NCT05120505	Children's Hospital of Fudan University	Phase 4
Completed	ERG/5-HTP in Fragile X Syndrome (FXS) NCT05030129	Elizabeth Berry-Kravis	Phase 2
Completed	Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome NCT04977986	Zynerba Pharmaceuticals, Inc.	Phase 3
Unknown	Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal NCT05295277	Bionano Genomics	—
Unknown	NIPD on cffDNA for Triplet Repeat Diseases NCT04698551	University Hospital, Montpellier	—
Unknown	Metformin in Patients With Fragile X NCT04141163	Rowan University	Phase 1 / Phase 2
Completed	A Trial of Metformin in Individuals With Fragile X Syndrome (Met) NCT03862950	University of Alberta	Phase 2
Enrolling By Invitation	Parent and Infant Inter(X)Action Intervention (PIXI) NCT03836300	RTI International	N/A
Enrolling By Invitation	Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents Wit NCT03802799	Zynerba Pharmaceuticals, Inc.	Phase 2 / Phase 3
Enrolling By Invitation	Early Check: Expanded Screening in Newborns NCT03655223	RTI International	—
Completed	Metformin in Children and Adults With Fragile X Syndrome NCT03722290	Université de Sherbrooke	Phase 2
Completed	A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome NCT03569631	Tetra Discovery Partners	Phase 2
Completed	Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) NCT03614663	Zynerba Pharmaceuticals, Inc.	Phase 2 / Phase 3
Completed	A Trial of Metformin in Individuals With Fragile X Syndrome NCT03479476	University of California, Davis	Phase 2 / Phase 3
Completed	Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS) NCT03624556	Parc de Salut Mar	N/A
Completed	An Initial Study of AZD7325 in Adults With Fragile X Syndrome NCT03140813	Children's Hospital Medical Center, Cincinnati	Phase 1
Completed	AFQ056 for Language Learning in Children With FXS NCT02920892	Elizabeth Berry-Kravis	Phase 2
Unknown	Cooperative Parent Mediated Therapy in Children With Fragile X Syndrome and Williams Syndrome NCT04610424	Bambino Gesù Hospital and Research Institute	N/A
Completed	Single Dose Pharmacokinetic (PK) Study NCT03109756	Healx AI	Phase 1
Completed	Treatment of Disruptive Behaviors in Fragile X Syndrome NCT03510156	Stanford University	N/A
Completed	Pediatric Patients With Metabolic or Other Genetic Disorders NCT02769949	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	—
Completed	Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome NCT02680379	Université de Sherbrooke	Phase 2
Completed	Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome NCT02642653	University of California, Davis	Phase 4
Completed	Neurophysiological and Acute Pharmacological Studies in FXS Patients NCT02998151	Children's Hospital Medical Center, Cincinnati	EARLY_Phase 1
Completed	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome NCT02616796	Stanford University	Phase 1 / Phase 2
Completed	A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile NCT02126995	Alcobra Ltd.	Phase 2
Completed	A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome NCT01894958	Neuren Pharmaceuticals Limited	Phase 2
Completed	Study of Acamprosate in Fragile x Syndrome NCT01911455	Children's Hospital Medical Center, Cincinnati	Phase 1
Completed	"Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients Wi NCT01855971	Parc de Salut Mar	Phase 2
Terminated	EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and pa NCT01711606	Novartis Pharmaceuticals	—
Completed	A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome NCT01750957	Hoffmann-La Roche	Phase 2
Completed	Cognitive Training for Fragile X Syndrome NCT02747394	University of California, Davis	N/A
Completed	Ganaxolone Treatment in Children With Fragile X Syndrome NCT01725152	Marinus Pharmaceuticals	Phase 2
Unknown	Validation of Saliva in the Esoterix Genetic Laboratories Fragile X Assay NCT01616589	Esoterix Genetic Laboratories, LLC	—
Completed	A Study of RO4917523 in Patients With Fragile X Syndrome NCT01517698	Hoffmann-La Roche	Phase 2
Completed	Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AF NCT01482143	Novartis Pharmaceuticals	Phase 1
Completed	Trial of Sertraline to Treat Children With Fragile X Syndrome NCT01474746	Randi J. Hagerman, MD	Phase 2
Terminated	Long-term, Safety and Tolerability Study of AFQ056 in Adolescent Patients With Fragile X Syndrome (Open-label) NCT01433354	Novartis Pharmaceuticals	Phase 2 / Phase 3
Terminated	An Open Label Extension Study in Subjects With Fragile X Syndrome NCT01555333	Seaside Therapeutics, Inc.	Phase 3
Completed	Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment NCT01364818	University of North Carolina, Chapel Hill	—
Terminated	Long-term, Safety, Tolerability and Efficacy Study of AFQ056 in Adult Patients With Fragile X Syndrome NCT01348087	Novartis Pharmaceuticals	Phase 2
Completed	Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragi NCT01325220	Seaside Therapeutics, Inc.	Phase 3
Completed	Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile NCT01282268	Seaside Therapeutics, Inc.	Phase 3
Suspended	A Study to Assess the Tolerability of a Single Dose of STX107 in Adults With Fragile X Syndrome NCT01325740	Seaside Therapeutics, Inc.	Phase 2
Completed	Safety and Efficacy of AFQ056 in Adolescent Patients With Fragile X Syndrome NCT01357239	Novartis Pharmaceuticals	Phase 2
Completed	Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome NCT01329770	Yolanda de Diego Otero	Phase 2
Completed	Safety and Efficacy of AFQ056 in Adult Patients With Fragile X Syndrome NCT01253629	Novartis Pharmaceuticals	Phase 2
Terminated	The Natural History of Reproductive and Overall Health in Girls and Women With a Pre-Mutation in the FMR1 Gene NCT01187524	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	—
Completed	Acamprosate in Youth With Fragile X Syndrome NCT01300923	Indiana University	Phase 2
Completed	Trial of Minocycline to Treat Children With Fragile X Syndrome NCT01053156	University of California, Davis	N/A
Completed	A Study With RO4917523 in Patients With Fragile X Syndrome NCT01015430	Hoffmann-La Roche	Phase 2
Terminated	An Open Label Extension Study of STX209 in Subjects With Fragile X Syndrome NCT01013480	Seaside Therapeutics, Inc.	Phase 2
Completed	Randomized Controlled Study of Donepezil in Fragile X Syndrome NCT01120626	Stanford University	Phase 2
Completed	A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107 NCT00965432	Seaside Therapeutics, Inc.	Phase 1
Completed	Biomarker and DNA Collection in Subjects Participating in Protocol 22003 NCT00892580	Seaside Therapeutics, Inc.	—
Completed	Riluzole in Fragile X Syndrome NCT00895752	Indiana University	Phase 4
Completed	A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions NCT00870974	Institute for Neurodegenerative Disorders	Phase 1
Completed	Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001 NCT00823368	Seaside Therapeutics, Inc.	—
Completed	Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome NCT00788073	Seaside Therapeutics, Inc.	Phase 2
Completed	Teaching Math Skills to Individuals With Fragile X Syndrome NCT01204151	Stanford University	N/A
Completed	Efficacy, Safety and Tolerability of AFQ056 in Fragile X Patients NCT00718341	Novartis	Phase 2
Completed	Open Label Study Investigating Safety and Efficacy of NPL2009 50 mg - 150 mg on Prepulse Inhibition Tests and NCT00637221	Neuropharm	Phase 1 / Phase 2
Completed	Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome NCT00858689	FRAXA Research Foundation	N/A
Completed	A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome NCT00420459	Indiana University School of Medicine	Phase 2
Completed	Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome NCT01254045	Stanford University	Phase 2
Completed	Protein Synthesis in the Brain of Patients With Fragile X Syndrome NCT00362843	National Institute of Mental Health (NIMH)	—
Completed	An Open-Label Trial of Donepezil in Fragile X Syndrome NCT00220584	Stanford University	Phase 1
Unknown	Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women NCT00334971	Massachusetts General Hospital	N/A
Completed	Effects of CX516 on Functioning in Fragile X Syndrome and Autism NCT00054730	RespireRx	Phase 2
Recruiting	The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome NCT00768820	The Chaim Sheba Medical Center	Phase 4